TP53 was also the most frequently mutated co-occurring gene in our study cohort, being present in 72% of patients, with the median OS being shorter in NSCLC–LM patients with mutated than wild-type TP53, although the difference was not statistically significant (p = 0.184). This evidence concerns the gene TP53 and non-small cell lung carcinoma.